0.00Open0.00Pre Close0 Volume0 Open Interest2.50Strike Price0.00Turnover0.00%IV-103.25%PremiumAug 16, 2024Expiry Date1.27Intrinsic Value100Multiplier24DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.36Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Invivyd Stock Discussion
• Newly outlined pathway provides a practical, expedient, repeatable immunobridging approach to potential emergency use authorization of serial, novel monoclonal antibodies (mAbs) to prevent and t...
Invivyd to Present Data at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and 2024 American Transplant Congress (ATC)
Invivyd announced its upcoming presentations at the 2024 ASCO Annual Meeting and the 2024 ATC. The presentations will cover preliminary subset analyses from the Phase 3 CANOPY trial of VYD222 (pemivibart), a monoclonal antibody aimed at preventing COVID-19.
At ASCO (May 31 – June 4, Chicago, IL), the focus will be on participants with sign...
Invivyd To Pursue Rapid Immunobridging Pathway To Potential EUA For Treatment Of COVID-19 In Moderately To Severely Immunocompromised People, Based On U.S. FDA Feedback
No comment yet